Medicines Co., Pfizer deal

Pfizer granted The Medicines Co. exclusive, worldwide rights to ApoA-I Milano. The variant of apolipoprotein A-1 HDL protein complexed with a phospholipid completed a Phase II trial in 2003 to treat acute coronary syndrome. Pfizer, which acquired the compound through its 2004 acquisition of Esperion Therapeutics Inc., has since discontinued development. ...